Quest Diagnostics (DGX) vs Illumina (ILMN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Illumina (ILMN) has outperformed Quest Diagnostics (DGX) over the past year, gaining 55.7% versus a gain of 35.0%. Over five years, DGX leads with a +66.7% price change compared with -46.4% for ILMN. Illumina is the larger company by market cap ($29.15 billion vs $28.42 billion), about 1.0 times the size, while Quest Diagnostics is growing revenue faster (+11.8% vs -0.7%).
On valuation, Quest Diagnostics trades at a lower forward P/E (21.6x vs 31.2x for Illumina). Quest Diagnostics pays a dividend yielding 1.31%, while Illumina does not currently pay one. Illumina converts more of its revenue into profit, with a net margin of 19.6% versus 9.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DGX | ILMN |
|---|---|---|
| Share price | $258.28 | $192.82 |
| Market cap | $28.42B | $29.15B |
| 1-day change | -0.31% | -3.90% |
| YTD return | +48.84% | +47.01% |
| 1-year return | +35.05% | +55.69% |
| 5-year return | +66.69% | -46.40% |
| P/E ratio (TTM) | 25.73 | 33.19 |
| Forward P/E | 21.55 | 31.19 |
| EPS (TTM) | $10.04 | $5.81 |
| Dividend yield | 1.31% | 0.00% |
| Annual dividend | $3.38 | $0.00 |
| Revenue (latest FY) | $11.04B | $4.34B |
| Revenue growth (YoY) | +11.78% | -0.66% |
| Net income (latest FY) | $992.00M | $850.00M |
| Gross margin | 33.21% | 66.08% |
| Operating margin | 14.10% | 18.58% |
| Net margin | 8.99% | 19.57% |
| 52-week high | $263.19 | $309.35 |
| 52-week low | $171.18 | $112.65 |
| Distance from 52-week high | -1.87% | -37.67% |
| Analyst consensus | buy | buy |
| Avg. price target upside | -0.39% | +35.59% |
| Average volume | 1.03M | 2.82M |
| Shares outstanding | 110.02M | 151.20M |
| Employees | 60,000 | 8,600 |
| Sector | Health Care | Health Care |
| Industry | Medical Specialities | Medical Specialities |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ILMN has outperformed DGX by 20.6 percentage points over the past year.
- Illumina trades at a higher earnings multiple (33.2x vs 25.7x trailing P/E).
- Quest Diagnostics offers a meaningfully higher dividend yield (1.31% vs 0.00%).
- Illumina is more profitable, keeping 19.6 cents of every revenue dollar as net income versus 9.0 cents for Quest Diagnostics.
- Quest Diagnostics grew revenue faster in its latest fiscal year (+11.78% vs -0.66%).
About Quest Diagnostics
DGX stock →Quest Diagnostics Incorporated provides diagnostic testing and services in the United States. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.
Health Care · Medical Specialities · 60,000 employees
About Illumina
ILMN stock →Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa.
Health Care · Medical Specialities · 8,600 employees
DGX vs ILMN FAQ
Which is bigger, Quest Diagnostics or Illumina?
Illumina (ILMN) is larger, with a market capitalization of $29.15B compared with $28.42B for Quest Diagnostics (DGX).
Which stock has performed better over the past year, DGX or ILMN?
ILMN returned +55.69% over the past 12 months, compared with +35.05% for DGX (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, DGX or ILMN?
DGX has the lower trailing P/E at 25.7, versus 33.2 for ILMN. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Quest Diagnostics or Illumina?
Quest Diagnostics pays a dividend yielding 1.31%, while Illumina does not currently pay a regular dividend.
Are Quest Diagnostics and Illumina in the same industry?
Yes. Both are classified in the Medical Specialities industry within the Health Care sector.